<DOC>
	<DOCNO>NCT00171015</DOCNO>
	<brief_summary>To evaluate efficacy valsartan 160 mg/HCTZ 25 mg patient adequately respond monotherapy olmesartan medoxomil 40 mg combination therapy olmesartan medoxomil 20 mg plus HCTZ 12.5 mg test hypothesis valsartan 160 mg/HCTZ 25 mg significantly reduce trough mean sit diastolic blood pressure ( MSDBP ) 4-week treatment nonresponder population .</brief_summary>
	<brief_title>VALORY Study Valsartan/Hydrochlorizide Patients Who Not Respond Adequately Olmesartan Medoxomil</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Females must either postmenopausal one year , surgically sterile use effective contraceptive method ( e.g . barrier method spermicide , intrauterine device , hormonal contraceptive ) . Patients essential hypertension : At Visit 1 , untreated patient MSDBP &gt; 100 mmHg &lt; 110 mmHg treat patient need MSDBP &lt; 110 mmHg . Untreated patient include soon safety laboratory parameter available , day Visit 1 . This inclusion visit record Visit 3 CRF . At Visit 2 , patient previously treat hypertension need MSDBP â‰¥ 100 mmHg &lt; 110 mmHg entrance first treatment phase . Patients previously treat hypertension MSDBP &lt; 100 mmHg Visit 2 continue washout phase evaluate regard BP criterion Visit 3 . Untreated patient perform Visit 2 . At Visit 3 , perform patient enter first treatment phase already Visit 2 , patient need MSDBP &gt; 100 mmHg &lt; 110 mmHg entrance first treatment phase . At Visit 4 , patient need MSDBP &gt; 90 mmHg entrance second treatment phase . MSDBP &gt; 110 mmHg MSSBP &gt; 180 mmHg Pregnant nursing woman Inability completely discontinue antihypertensive medication safely period 2 week , require protocol Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>VALSARTAN</keyword>
	<keyword>HYDROCHLOROTHIAZIDE</keyword>
	<keyword>OLMESARTAN</keyword>
	<keyword>HYPERTENSION</keyword>
</DOC>